DDMS
(Synonyms: Dibromo-dodecenyl-methylsulfimide) 目录号 : GC10778
A potent inhibitor of 20-HETE synthesis
Cas No.:206052-03-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
DDMS is a CYP4A2 enzyme inhibitor.
Biosynthesis of 20-HETE from arachidonic acid by the cytochrome P450 4A (CYP450 4A) isoforms is a key component of vascular homeostasis, especially in renal circulation.
In vitro: To determine whether inhibition of 20-HETE contributes to the vasodilatory effects of NO, the effects of DDMS on the response to SNP were examined in rat renal arterioles preconstricted with phenylephrine). Results showed that after DDMS treatment, SNP could increase vascular diameter by only 17% [1].
In vivo: The effects of DDMS on the mean arterial pressure and renal blood flow responses to infusion of an NO donor and a synthase inhibitor were also examined. It was found that infusion of MAHMA NONOate at 1, 3, 5, and 10 nmol/min was able to reduce mean arterial pressure by 16, 30, 40, and 48 mm Hg and lowered renal vascular resistance by 15 %, 26 %, 30%, and 34% of control. In addition, after DDMS treatment at 10 mg/kg, the mean arterial pressure and renal vascular resistance responsed to 1-hexamine, 6-(2-hydroxy-1-methyl-2-nitrohydrazino)N-methyl averaged only 20% of those seen during control [1].
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] Alonso-Galicia, M. ,Drummond, H.A.,Reddy, K.K., et al. Inhibition of 20-HETE production contributes to the vascular responses to nitric oxide. Hypertension 29, 320-325 (1997).
| Cas No. | 206052-03-1 | SDF | |
| 别名 | Dibromo-dodecenyl-methylsulfimide | ||
| 化学名 | 12,12-dibromo-N-(methylsulfonyl)-11-dodecenamide | ||
| Canonical SMILES | BrC(=CCCCCCCCCCC(=O)NS(=O)(=O)C)Br | ||
| 分子式 | C13H23Br2NO3S | 分子量 | 433.2 |
| 溶解度 | ≤20mg/ml in DMSO;30mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3084 mL | 11.542 mL | 23.084 mL |
| 5 mM | 0.4617 mL | 2.3084 mL | 4.6168 mL |
| 10 mM | 0.2308 mL | 1.1542 mL | 2.3084 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。